Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Affitech, Kael Co. Ltd. deal

March 8, 2010 8:00 AM UTC

Affitech sold its remaining rights to GV1001 to Kael's Kael-GemVax Co. Ltd. subsidiary for $1 million and will be no longer eligible for milestones and royalties. GV1001 is a cancer vaccine targetin...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article